

Author Index

BR: Book review

A

- Ackland, M.J., *see* Smith, D.A. 406, 479
 Allen, R., *see* Hughes, B. 89
 Arlington, S., Accelerating drug discovery: creating the right environment 547

B

- Badger, A.M. and Lee, J.C., Advances in antiarthritic therapies 427
 Baldessarini, R.J., *see* Kebabian, J.W. 333
 Bancroft, D., *see* Maier, E. 315
 Banks, M., *see* Harding, D. 385
 Baxter, A.D., Meeting client needs in combinatorial chemistry: a service company perspective 307
 Beck-Sickinger, A., Receptor Signal Transduction Protocols (BR) 454
 Bigge, C.F., *see* Boxer, P.A. 219
 Binnie, A., *see* Harding, D. 385
 Binns, R. and Driscoll, B., Biogen v. Medeva – the highest court in the UK delivers judgement 117
 Blunck, M., *see* Mullen, A. 179
 Boger, D., Cancer Therapeutics: Experimental and Clinical Agents (BR) 217
 Bohlin, L., *see* Bruhn, J.G. 243
 Borschardt, V.J., *see* Gangwar, S. 148
 Boxer, P.A. and Bigge, C.F., Mechanisms of neuronal cell injury/death and targets for drug intervention 219
 Bradley, D., NO escape 3
 Bradley, D., Race to displace Taxol 87
 Bradley, D., Nervous Hawaiian plants 177
 Bradley, D., Sweet signal transduction 214
 Bradley, D., Getting the nano-needle 452
 Bradley, D., Genes and painkillers 456
 Bradley, D., Heart of the matter 508
 Bradley, M., *see* Egner, B.J. 102
 Bruhn, J.G. and Bohlin, L., Molecular pharmacognosy: an explanatory model 243
 Bryant, M.S., *see* Korfmacher, W.A. 532
 Buckle, D.R. and Hedgecock, C.J.R., Drug targets in inflammation and immunomodulation 325

C

- Cavalla, D., Outsourcing in the Pharmaceutical Industry (BR) 178
 Cavalla, D., Architecture of R&D – a conceptual framework for collaboration 200
 Cheresch, D.A., *see* Mousa, S.A. 187
 Cimarusti, C.M., Project acceleration: the case for quantum change 1
 Condra, J.H., *see* Vacca, J.P. 261
 Cox, K., *see* Korfmacher, W.A. 532

D

- Dalgleish, A.G., *see* Marriott, J.B. 273
 D'Amato, M., *see* Makovec, F. 283
 De Lucca, G.V., Erickson-Viitanen, S. and Lam, P.Y.S., Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule 6
 de Vries, P., *see* Villalón, C.M. 294
 Dodds, D.R., *see* Zaks, A. 513
 Drews, J., Strategic choices facing the pharmaceutical industry: a case for innovation 72
 Drews, J. and Ryser, S., Pharmaceutical innovation between scientific opportunities and economic constraints 365
 Driscoll, B., *see* Binns, R. 117

E

- Egner, B.J. and Bradley, M., Analytical techniques for solid-phase organic and combinatorial synthesis 102
 Erickson-Viitanen, S., *see* De Lucca, G.V. 6

F

- Faragher, R.G.A. and Shall, S., Gerontology and drug development: the challenge of the senescent cell 64
 Fernandes, P.B., Society for Biomolecular Screening – origin and future role 361
 Fogarty, S., *see* Harding, D. 385
 Fong, T.A.T., *see* Shawver, L.K. 50

G

- Gangwar, S., Pauletti, G.M., Wang, B., Siahaan, T.J., Stella, R.T. and Borschardt, V.J., Prodrug strategies to enhance the intestinal absorption of peptides 148
 Gardner, M., Molecular Diversity and Combinatorial Chemistry: Libraries and Drug Discovery (BR) 177
 Goldman, M.E., Cost-effective Strategies for Automated and Accelerated High-throughput Screening (BR) 88
 Goldman, M.E., Accelerating drug discovery 357
 Grausz, J.D., Genome sequencing and analysis 510

H

- Harding, D., Banks, M., Fogarty, S. and Binnie, A., Development of an automated high-throughput screening system: a case history 385
 Harvey, A.L., Win-win licensing deals 312
 Hedgecock, C.J.R., *see* Buckle, D.R. 325
 Helander, H.F., *see* Widzowski, D. 341
 Hemmilä, I. and Webb, S., Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications 373
 Herdewijn, P., Structural requirements for antiviral activity in nucleosides 235
 Hill, D.C., Monitoring performances and ensuring quality in drug discovery alliances 29
 Hillery, A. and Lloyd, A., New delivery systems for macromolecules 402
 Holst, J.J., Non-insulin dependent diabetes mellitus: new drugs? 128
 Hruby, V.J., Prospects for peptidomimetic drug design 165
 Hughes, B., Owens, R., Perry, M., Warreallow, G. and Allen, R., PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs 89
 Hughes, D., Grist to the 'Mill' 2
 Hughes, D., Biopartnering on the net 4
 Hughes, D., SmithKline Beecham first BIA patron 4

- Hughes, D., Automated discovery – faster and cheaper, but better? 40
- Hughes, D., GATT and Patent Reform: The Global Strengthening of Patent Protection and the Implications for the Pharmaceutical Industry (BR) 130
- Hughes, D., Cambridge Combinatorial 170
- Hughes, D., Emerging Drugs: the Prospect for Improved Medicines (BR) 313
- Hughes, D., Modern Strategy for Preclinical Pharmaceutical R&D (BR) 313
- Hunter, P., Growing threat of Gram-positive resistance – a challenge to the industry 49
- J**
- Jack, D., Unique post-doc system at SUNBOR 3
- Jain, K.K., Molecular genetic profiling 310
- Jones, B.C., *see* Smith, D.A. 406, 479
- K**
- Kebabian, J.W., Tarazi, F.I., Kula, N.S. and Baldessarini, R.J., Compounds selective for dopamine receptor subtypes 333
- Keifer, P.A., High-resolution NMR techniques for solid-phase synthesis and combinatorial chemistry 468
- Kennedy, A., Managing the drug discovery/development interface 436
- Kerr, D.I.B., The GABA Receptors (2nd edn) (BR) 131
- Korfmacher, W.A., Cox, K., Bryant, M.S., Veals, J., Ng, K., Watkins R. and Lin C-C., HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process 532
- Kubinyi, H., QSAR and 3D QSAR in drug design. Part 1: methodology 457
- Kubinyi, H., QSAR and 3D QSAR in drug design. Part 2: applications and problems 538
- Kula, N.S., *see* Kebabian, J.W. 333
- Kyle, D.J., *see* Zheng, Q. 229
- L**
- Lam, P.Y.S., *see* De Lucca, G.V. 6
- Langston, S., Peptidomimetics and small molecule design 254
- Leach, M., Virtual molecules! 39
- Leach, M., Marvellous microplates 174
- Leach, M., Drug discovery on a credit card 253
- Lee, J.C., *see* Badger, A.M. 427
- Lehrach, H., *see* Maier, E. 315
- Lin, C-C., *see* Korfmacher, W.A. 532
- Lipson, K.E., *see* Shawver, L.K. 50
- Lloyd, A.W., Monitor 34, 79, 122, 161, 206, 247, 301, 351, 391, 445, 499, 554
- Lloyd, A.W., Stereochemistry: handling interactions 127
- Lloyd, A.W., Modifying the drug discovery/drug development paradigm 397
- Lloyd, A.W., *see* Hillery, A. 402
- M**
- Maier, E., Meier-Ewart, S., Bancroft, D. and Lehrach, H., Automated array technologies for gene expression profiling 315
- Makovec, F. and D'Amato, M., CCK B/Gastrin receptor antagonists as potential drugs for peptic ulcer therapy 283
- Marriott, J.B., Westby, M. and Dalgleish, A.G., The therapeutic potential of TNF- α inhibitors old and new 273
- McMahon, G., *see* Shawver, L.K. 50
- Meier-Ewart, S., *see* Maier, E. 315
- Mezey, P.G. and Walker, P.D., Fuzzy molecular fragments in drug research 132
- Möller, K.E., *see* Mullen, A. 179
- Mousa, S.A. and Cheresh, D.A., Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications 187
- Mullen, A., Blunck, M. and Möller, K.E., Comparison of some major information resources in pharmaceutical competitor tracking 179
- Murcko, M., Molecular Modeling: Basic Principles and Applications (BR) 364
- N**
- Neamati, N., Sunder, S. and Pommier, Y., Design and discovery of HIV-1 integrase inhibitors 487
- Ng, K., *see* Korfmacher, W.A. 532
- O**
- Owens, R., *see* Hughes, B. 89
- P**
- Pauletti, G.M., *see* Gangwar, S. 148
- Perry, M., *see* Hughes, B. 89
- Plowman, G.D., *see* Shawver, L.K. 50
- Pommier, Y., *see* Neamati, N. 487
- R**
- Reiss, M., Ethical Issues in Drug Research: Through a Glass Darkly (BR) 49
- Repke, K.R.H., Towards the discovery of digitalis derivatives with inotropic selectivity 110
- Rishton, G.M., Reactive compounds and in vitro false positives in HTS 382
- Robinson, C., Lipid-based therapeutics: a different approach 449
- Rogers, M.V., Light on high-throughput screening: fluorescence-based assay 156
- Rogers, M.V., High-throughput screening 209, 251, 306, 395, 503
- Ross, G.M., Catecholamine absorbing proteins (CATNAPS) 36
- Ruwart, M.J., Successful Scientific Writing (BR) 5
- Ryser, S., *see* Drews, J. 365
- S**
- Saxena, P.R., *see* Villalón, C.M. 294
- Shall, S., *see* Faragher, R.G.A. 64
- Shawver, L.K., Lipson, K.E., Fong, T.A.T., McMahon, G., Plowman, G.D. and Strawn, L.M., Receptor tyrosine kinases as targets for inhibition of angiogenesis 50
- Siahaan, T.J., *see* Gangwar, S. 148
- Smith, D.A., Ackland, M.J. and Jones, B.C., Properties of cytochrome P450 isoenzymes and their substrates. Part 1: active site characteristics 406
- Smith, D.A., Ackland, M.J. and Jones, B.C., Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates 479
- Stead, P., Natural products drug discovery 256
- Steele, P., Neuropeptide patenting 25
- Stella, R.T., *see* Gangwar, S. 148
- Strawn, L.M., *see* Shawver, L.K. 50

Streng, W.H., Physical chemical characterization of drug substances 415
Sunder, S., *see* Neamati, N. 487

T

Tarazi, F.I., *see* Kebabian, J.W. 333
Terrett, N., Combinatorial chemistry 37, 81, 124, 163, 207, 250, 304, 354, 394, 447, 502, 556
Thorne, M., Advanced technologies for information extraction 43
Thorne, M., Infotech Pharma: the information revolution in the pharmaceutical industry 167
Triggle, D.J., Stereoselectivity of drug action 138

V

Vacca, J.P. and Condra, J.H., Clinically effective HIV-1 protease inhibitors 261
Veals, J., *see* Korfmacher, W.A. 532
Villalón, C.M., de Vries, P. and Saxena, P.R., Serotonin receptors as cardiovascular targets 294

W

Walker, P.D., *see* Mezey, P.G. 132
Wallace, R.W., Emerging molecular targets 38, 82, 125, 164, 207, 250, 305, 355, 396, 448, 504, 558
Wallace, R.W., New HIV protease inhibitors 83
Wallace, R.W., Towards effective CF treatment 212
Wallace, R.W., High-throughput screening 355, 557
Wallace, R.W., What's your poison? 359
Wallace, R.W., Working with worms 399
Wallace, R.W., Combinatorial biosynthesis 505
Wang, B., *see* Gangwar, S. 148
Warrellow, G., *see* Hughes, B. 89
Watkins, R., *see* Korfmacher, W.A. 532
Webb, S., *see* Hemmilä, I. 373
Westby, M., *see* Marriott, J.B. 273
Widzowski, D., Helander, H.F. and Wu, E.S.C., Selective muscarinic M1 antagonists: drug design and discovery 341

Willems, H., New ligands for peptide receptors 38
Willems, H., Update on endothelins 85
Willems, H., Moos chooses Mitokor 211
Willems, H., New combinatorial chemistry 214
Williams, J.P., Hard graft and 'hoopla' – ACS highlights 362
Wright, J.L., Design and discovery of neuropeptide Y1 receptor antagonists 19
Wu, E.S.C., *see* Widzowski, D. 341

Z

Zaks, A. and Dodds, D.R., Application of biocatalysis and biotransformations to the synthesis of pharmaceuticals 513
Zheng, Q. and Kyle, D.J., Computational screening of combinatorial libraries via multiple copy sampling 229